inavolisib + abemaciclib + letrozole

This is a combination therapy of three small molecule drugs: **inavolisib**, a PI3K alpha-selective inhibitor; **abemaciclib**, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor; and **letrozole**, a nonsteroidal aromatase inhibitor. The combination is being investigated for the treatment of **hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer** with PIK3CA mutations. - Inavolisib targets the PI3K-AKT-mTOR pathway by selectively inhibiting the alpha isoform of phosphoinositide 3-kinase (PIK3CA), impeding proliferative and survival signals in cancer cells. - Abemaciclib inhibits CDK4 and CDK6, causing cell cycle arrest in G1 and preventing cancer cell proliferation. - Letrozole inhibits aromatase, lowering estrogen production and minimizing the growth stimulus for HR+ breast cancer cells. This combination is being studied in advanced clinical trials and is considered a novel strategy for patients with tumors harboring both hormone receptor expression and PIK3CA mutations[2][3].

Other names

inavolisib + abemaciclib + letrozole